Alzheimer's disease

被引:485
作者
Blennow, Kaj [1 ]
de Leon, Mony J.
Zetterberg, Henrik
机构
[1] Sahlgrens Univ Hosp, Clin Neurochem Lab, Dept Neurosci & Physiol, SE-43180 Molndal, Sweden
[2] NYU, Sch Med, Ctr Brain Hlth, Dept Psychiat, New York, NY USA
[3] Nathan S Kline Inst Psychiat Res, New York, NY USA
关键词
D O I
10.1016/S0140-6736(06)69113-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Alzheimer's disease is the most common cause of dementia. Research advances have enabled detailed understanding of the molecular pathogenesis of the hallmarks of the disease-ie, plaques, composed of amyloid beta (A beta), and tangles, composed of hyperphosphorylated tau. However, as our knowledge increases so does our appreciation for the pathogenic complexity of the disorder. Familial Alzheimer's disease is a very rare autosomal dominant disease with early onset, Caused by mutations in the amyloid precursor protein and presenilin genes, both linked to A beta metabolism. By contrast with familial disease, sporadic Alzheimer's disease is very common with more than 15 million people affected worldwide. The cause of the sporadic form of the disease is unknown, probably because the disease is heterogeneous, caused by ageing in concert with a complex interaction of both genetic and environmental risk factors. This seminar reviews the key aspects of the disease, including epidemiology, genetics, pathogenesis, diagnosis, and treatment, as well as recent developments and controversies.
引用
收藏
页码:387 / 403
页数:17
相关论文
共 184 条
[1]   Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression - A randomized controlled trial [J].
Aisen, PS ;
Schafer, KA ;
Grundman, M ;
Pfeiffer, E ;
Sano, M ;
Davis, KL ;
Farlow, MR ;
Jin, S ;
Thomas, RG ;
Thal, LJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (21) :2819-2826
[2]   The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease [J].
Aisen, PS .
LANCET NEUROLOGY, 2002, 1 (05) :279-284
[3]   Association between hormone replacement therapy and dementia: is it time to forget? [J].
Almeida, OP ;
Flicker, L .
INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 (02) :155-164
[4]  
Alzheimers Assoc, 1998, NEUROBIOL AGING, V19, P109
[5]  
Areosa SA, 2005, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003154.PUB4
[6]   Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment [J].
Arnáiz, E ;
Jelic, V ;
Almkvist, O ;
Wahlund, LO ;
Winblad, B ;
Valind, S ;
Nordberg, A .
NEUROREPORT, 2001, 12 (04) :851-855
[7]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[8]   Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Aβ production in APP23 transgenic mice [J].
Bayer, TA ;
Schäfer, S ;
Simons, A ;
Kemmling, A ;
Kamer, T ;
Tepest, R ;
Eckert, A ;
Schüssel, K ;
Eikenberg, O ;
Sturchler-Pierrat, C ;
Abramowski, D ;
Staufenbiel, M ;
Multhaup, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (24) :14187-14192
[9]  
Bentham P, 2004, LANCET, V363, P2105
[10]   Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and β-amyloid accumulation in a mouse model of Alzheimer's disease [J].
Bergamaschini, L ;
Rossi, E ;
Storini, C ;
Pizzimenti, S ;
Distaso, M ;
Perego, C ;
De Luigi, A ;
Vergani, C ;
De Simoni, MG .
JOURNAL OF NEUROSCIENCE, 2004, 24 (17) :4181-4186